Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-5: Retatrutide vs Tirzepatide in Obesity
NCT06662383Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of retatrutide in obesity, sponsored by Eli Lilly and Company. Started Nov 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06662383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662383.